Heterogeneity of efficacy by HbA@c was observed for the primary endpoint of angina frequency ( Pinteraction = @ ) , the key secondary endpoint of SL NTG use ( Pinteraction = @ ) , SAQ angina frequency ( Pinteraction = @ ) , and SAQ treatment satisfaction ( Pinteraction = @ ) with greater efficacy of ranolazine in those with higher HbA@c values , increasing continuously from HbA@c levels > @ % .